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Abstract 
Purpose. To describe the epidemiology of critical disease in HIV-infected patients during the current highly 
active antiretroviral therapy (HAART) era and to identify hospital mortality predictors. 
Methods. A longitudinal, retrospective observational study was made of HIV-infected adults admitted to the 
ICU in two Spanish hospitals between 1 January 2000 and 31 December 2014. Demographic and HIV-related 
variables were analyzed, together with comorbidities, severity scores, reasons for admission and need for 
organ support. The chi-squared test was used to compare categorical variables, while continuous variables 
were contrasted with the Student's t-test, Mann–Whitney U-test or Kruskal–Wallis test, assuming an alpha 
level = 0.05. Multivariate logistic regression analysis was used to calculate odds ratios for assessing 
correlations to mortality during hospital stay. Joinpoint regression analysis was used to study mortality trends 
over time. 
Results. A total of 283 episodes were included for analyses. Hospital mortality was 32.9% (95%CI: 21.2–
38.5). Only admission from a site other than the Emergency Care Department (OR 3.64, 95%CI: 1.30–
10.20; p = 0.01), moderate–severe liver disease (OR 5.65, 95%CI: 1.11–28.87; p = 0.04) and the APACHE II 
score (OR 1.14, 95%CI: 1.04–1.26; p < 0.01) and SOFA score at 72 h (OR 1.19, 95%CI: 1.02–1.40; p = 0.03) 
maintained a statistically significant relationship with hospital mortality. 
Conclusions. Delayed ICU admission, comorbidities and the severity of critical illness determine the 
prognosis of HIV-infected patients admitted to the ICU. Based on these data, HIV-infected patients should 
receive the same level of care as non-HIV-infected patients, regardless of their immunological or nutritional 
condition.  
Resumen 
Objetivos. Describir la epidemiología de la patología crítica en el paciente infectado por VIH durante la era 
de tratamiento antirretroviral de gran actividad actual y encontrar predictores de mortalidad hospitalaria. 
Métodos. Estudio observacional, retrospectivo y longitudinal que incluye pacientes infectados por VIH 
adultos ingresados en las UCI de hospitales de Galicia, entre el 1 de enero de 2000 y el 31 de diciembre de 
2014. Analizamos variables demográficas y relacionadas con la infección por el VIH, comorbilidades, 
puntuaciones de gravedad, motivo de ingreso y necesidad de soporte de órganos. Empleamos la prueba de la 
Chi-cuadrado para comparar las variables categóricas y las pruebas de la T-Student, U de Mann-Whitney o H 
de Kruskal-Wallis para las variables continuas, asumiendo un error α = 0,05. Utilizamos la regresión logística 
multivariante para calcular la OR de la asociación con la mortalidad hospitalaria. Aplicamos análisis de 
regresión de joinpoint para estudiar la tendencia temporal de mortalidad. 
Resultados. Incluimos 283 episodios. La mortalidad hospitalaria fue del 32,9% (IC 95% = 21,2-38,5%). El 
ingreso no procedente de Urgencias (OR 3,64; IC 95% =  1,30-10,20; p = 0,01), la enfermedad hepática 
moderada-grave (OR 5,65; IC 95% = 1,11-28,87; p = 0,04), el APACHE II (OR 1,14; IC 95% = 1,04-1,26; 
p < 0,01) y el SOFA a las 72 h (OR 1,19; IC 95% =  1,02-1,40; p = 0,03) se relacionan con la mortalidad 
hospitalaria en el análisis multivariante. 
Conclusiones. El retraso en el ingreso en UCI, las comorbilidades y la gravedad del episodio determinan el 
pronóstico del paciente infectado por VIH ingresado en UCI. Los pacientes con VIH deberían recibir el 
mismo nivel de cuidados que los pacientes no infectados por VIH, independientemente de su estado 
inmunológico o nutricional. 
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Introduction 
The introduction of antiretroviral therapy (ART) has meant a drastic change in HIV-infected 
patients’ prognoses. Since its introduction, survival rates have continued to increase, even in 
developing countries.1, 2, 3 Moreover, high activity ART (HAART) has reduced the incidence of 
AIDS-related diseases and hospitalizations.4 Among patients with good immunovirological 
conditions, HIV infection has become a chronic disease. However, immune system restoration is 
incomplete in these patients and there remains an inflammatory condition which, in the long-term, 
is related to pathologies such as cancer and cardiovascular diseases. This chronic inflammatory 
profile, along with longer survival and possible toxicity accumulation from HAART, will mean 
that HIV-infected elderly patients have a high burden of “special” comorbidities known as HIV-
associated non-AIDS (HANA)5 which will cause their hospital admissions. 
 
HAART has also led to a significant change in both the profile and prognosis of HIV patients 
admitted to intensive care units (ICU). At the start of the pandemic in the early 1980s, 70% of 
admissions were due to respiratory failure secondary to pneumonia caused by Pneumocystis 
jiroveci (formerly known as Pneumocystis carinii, hence its acronym: PCP). However, since 
HAART was introduced, the rate of patients admitted to the ICU with AIDS-related diseases has 
dropped, as has the associated mortality. In Europe and North America, short-term mortality of 
approximately 20–30% (survival higher than 90% in the ICU) has been reported, as has survival of 
85% at one year and higher than 70% at two 
years.6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 Although with higher mortality than in Europe and 
North America, decreased mortality has also been observed in countries such as Brazil, Mexico, 
China, Taiwan and Australia, where intra-ICU and hospital mortality varies from 37% to 68% and 
48% to 68%, respectively.24, 25, 26, 27, 28, 29, 30 In Spain, higher mortality has been published compared 
with other developed countries (36.5%, 67.9% and 80.9% at 30, 60 and 90 days, 
respectively)31 without evidence of a decrease over the HAART period.32 
However, despite the decreased mortality in HIV patients admitted to the ICU, this is still greater 
than in non-HIV patients.20, 23, 31 Results from analyses of prognostic factors in this patient group 
have varied. Some study authors have concluded that the patient's immunovirological condition 
determines the prognosis,26, 28 while others have stated that prognosis depends on disease severity 
that led to ICU admission19, 21, 22, 25, 27, 33 and comorbidities.21, 22, 31 
 
Our study aim was thus to describe the epidemiology of critical pathology in HIV patients in a 
cohort of patients admitted to ICU, during the current HAART period and to identify factors that 
predict mortality during hospital admission. 
Methods 
Study scope 
The study was performed in the ICUs of Complexo Hospitalario Universitario de A Coruña (36 
beds) and Complexo Hospitalario Universitario de Ourense (22 beds), two public hospitals located 
in the northwest of Spain, serving an approximate population of 500,000 inhabitants. 
Study period 
Data were collected from 1 January 2000 to 31 December 2014. 
Study design 
This was a longitudinal, retrospective, observational study. 
Inclusion criteria 
Inclusion criteria included: ICU admission from the community, hospital ward or another 
hospital; HIV infection diagnosed previously or during ICU admission; age older than 18 years. 
Exclusion criteria 
Patients readmitted to the ICU during the same hospital admission were excluded. 
Patient recruitment 
Patients were identified for inclusion using the two hospitals’ clinical documentation systems. 
Ethics 




Clinical records for each admission were reviewed. We analyzed sociodemographic data (age and 
sex); comorbidities (defined according to the Charlson comorbidity index – CCI, see Appendix A. 
Supplementary data); date of HIV infection diagnosis; most recent CD4 count and viral load (VL) 
(in the event that these data were unavailable for the six months prior to admission, we used the 
first post-admission data if determined during the first week of ICU admission); HAART (active 
prescription of at least three antiretrovirals from at least two classes, unless there was evidence of 
therapeutic non-compliance); nutritional status (cachexia, reported during physical examination, 
and albumin levels upon ICU admission); reason for ICU admission; severity at admission 
(APACHE II score); organ dysfunction (SOFA score at admission and 72 h); organ support during 
admission (vasopressors, mechanical ventilation and renal replacement techniques [RRTs]); 
ICU/hospital length of stay (LOS) and ICU and in-hospital mortality. We also recorded ART 
administration during the ICU stay. 
 
Admission from ED (Emergency Department) was defined as ICU admission right away from ED. 
Admission form medical or surgical ward was defined as “admission not from E.D.” 
 
Patients with new positive tests during hospital admission and before discharge from the ICU were 
considered newly diagnosed with an HIV infection. 
 
Co-infection with Hepatitis C Virus (HCV) was defined as positive RNA-HCV and Hepatitis B 
Virus infection (HBV) was defined as positive surface antigen (HBsAg). 
 
To identify changes over time, we established three periods of 5 years (1: 2000–2004, 2: 2005–
2009, 3: 2010–2014). 
Sample size rationale 
A total of 283 patients were recruited during the study period. This sample size allows estimating 
parameters with a precision of ±6.5% at a confidence level of 95%. Furthermore, it allows to 
detect as statistically significant differences in hospital mortality rates of 16% or higher, assuming 
a mortality rate around 25% and an expected exposure to a risk factor of 50% (confidence level 
95%, power level 80%). 
Statistical analysis 
Continuous variables are shown as mean ± standard deviation (SD) or median and p25–p75; 
qualitative variables are shown as number and percentage. 
 
We compared patients who survived hospital admission with those who died during their hospital 
stay using the Chi-square test for categorical variables and Student's t-test or the Mann–
Whitney U test for continuous variables, assuming an alpha level = 0.05. We compared the three 
time periods using Kruskal–Wallis H for quantitative variables, and Chi-square for categorical 
variables. Trends in mortality during the study period were investigated by a joinpoint regression 
analysis. We used logistic regression to calculate OR values to evaluate the association with 
mortality during the hospital stay. Variables associated with hospital mortality (p < 0.05) on 
univariate analyses were included in the multivariate analysis. 
 
Statistical analyses were performed using IBM SPSS Statistics, Version 19.0. (IBM Corp., 
Armonk, NY). 
Results 
A total of 297 admissions were recorded; among these, 14 patients were admitted twice, so only 
the initial 283 episodes were included for final analyses. The patient sample characteristics are 
shown in Table 1. 
Table 1. Baseline characteristics of patients. 
 All Hospital mortality  
  No Yes 
p value 
 n = 283 190 (67.1) 93 (32.9) 
     
Age (years) 43.34 ± 9.60 43.20 ± 9.67 43.63 ± 9.53 0.73 
Male sex 206 (72.8) 132 (69.5) 74 (79.5) 0.08 
Admission from ED 160 (56.5) 128 (67.3) 32 (34.4) <0.01 
HIV infection 
Diagnosis at this admission 33 (11.7) 16 (8.4) 17 (18.2) 0.02 
Diagnosis in the ICU 23 (8.1) 13 (6.8) 10 (10.7) 0.26 
HAART 155 (54.8) 112 (58.9) 43 (46.2) 0.04 
HAART in the ICU 111 (39.2) 87 (45.8) 24 (25.8) <0.01 
OI prophylaxis 41 (14.5) 23 (12.1) 18 (19.3) 0.10 
AIDS 195 (68.9) 124 (65.2) 71 (76.3) 0.06 
Years of infection 9 (3, 16) 10 (5, 16) 8 (1, 16) 0.10 
CD4 count (cell/mL) 167.0 (53.5, 414.0) 204.0 (74.0, 493.5) 80.0 (29.0, 236.5) <0.01 
Viral load (log) 2.9 (0.0, 5.3) 2.6 (0.0, 5.0) 4.5 (1.1, 5.5) 0.02 
Viral load suppressed 64 (22.6) 47 (29.7) 17 (24.3) 0.40 
Comorbidities and nutritional status (see . Appendix A. Supplementary data) 
DM free of complications 10 (3.5) 5 (2.6) 5 (5.4) 0.24 
DM with complications 2 (0.7) 2 (1.0) 0 (0) 0.32 
Cardiac disease 13 (4.6) 10 (5.2) 3 (3.2) 0.44 
Lung disease 25 (8.8) 20 (10.5) 5 (5.3) 0.15 
Liver disease 185 (65.4) 122 (64.2) 63 (67.7) 0.56 
M-S liver disease 37 (13.1) 18 (9.4) 19 (20.4) 0.01 
Renal disease 5 (1.8) 2 (1.0) 3 (3.2) 0.19 
Hepatitis C Virus (HCV) 170 (60.1) 114 (60.0) 56 (60.2) 0.97 
Hepatitis B Virus (HBV) 36 (12.7) 27 (14.2) 9 (9.7) 0.28 
HCV + HBV 24 (8.5) 20 (10.5) 4 (4.3) 0.08 
Charlson Comorbidity Index 7 (3, 7.25) 6 (2, 7) 7 (6, 8) <0.01 
Cachexia 70 (24.7) 35 (18.4) 35 (37.6) <0.01 
Albumin (g/dL) 2.6 (2.1, 3.3) 2.7 (2.2, 3.3) 2.3 (1.8, 3.0) <0.01 
Diagnosis at admission (see . Appendix A. Supplementary data) 
Severe sepsis/septic shock 140 (49.5) 83 (43.7) 57 (61.3) <0.01 
Cardiac 55 (19.4) 48 (25.2) 7 (7.5) <0.01 
Trauma 19 (6.7) 15 (7.9) 4 (4.3) 0.26 
Neurological 11 (3.9) 4 (2.1) 7 (7.5) 0.04 
Organ support during admission 
Mechanical ventilation 172 (60.8) 91 (47.9) 81 (87.1) <0.01 
Vasoactive drugs 114 (40.3) 55 (28.9) 59 (63.4) <0.01 
Renal replacement therapy 31 (11.0) 9 (4.7) 22 (23.6) <0.01 
Complications 
Superinfection 41 (14.5) 19 (10.0) 22 (23.6) <0.01 
Severity scores 
APACHE II 18.05 ± 9.05 14.90 ± 7.97 24.41 ± 7.69 <0.01 
SOFA score 6 (3, 9) 4 (2, 8) 9 (5, 12) <0.01 
SOFA score 72 h 5 (2, 8) 3 (2, 7) 7 (4, 11) <0.01 
SOFA 0–72 h −1 (−3, 1) −1 (−3, 0) 0 (−2, 3) <0.01 
     
 
Numbers reported as n (%) and mean ± standard deviation or median (p25–p75). 
ED: Emergency Department; HAART: high-activity antiretroviral therapy; OI: opportunistic infection; DM: diabetes 
mellitus; M–S liver disease: moderate–severe liver disease. 
A total of 71 patients (25.1%) died during their admission to the ICU, while another 22 died before 
hospital discharge, translating to a total hospital mortality of 32.9% (95% CI = 21.2–38.5%). 
Among these 14 patients who were admitted twice, 11 (78.6%) died during hospital stay. 
 
Median ICU and hospital LOS were 52, 13 and 189, 37 days, respectively. 
 
In this sample, 68.9% fulfilled the AIDS criteria following CDC 1993 criteria.34 Following new 
definitions35 11.7% patients were in stage 0, 12.0% in stage 1, 14.1% in stage 2, 59% in stage 3 
and 3.2 in stage unknown. Among patients with a known HIV infection, 62% were 
under HAART at the time of admission (54.8% of the total sample). Their CD4 count was 167.0 
(53.5, 414.0) cells/mm3 and VL was log 2.9 (0.0, 5.3), with 22.6% having an undetectable VL. 
Patients who survived their hospital admission, compared with those who died, received ART 
more frequently (58.9 compared with 46.2%, p < 0.01) and had a better immunovirological profile: 
higher CD4 count (204.0 (74.0, 493.5) cell/mL compared with 80.0 (29.0, 236.5), p < 0.01), and 
lower VL (2.6 (0.0, 5.0) log compared with 4.5 (1.1, 5.5), p = 0.02). 
 
The most common comorbidity in this sample was liver disease (present in 65.4%), with 60.1% 
co-infected with HCV (Appendix A. Supplementary data, Table e1). Their CCI (median, IQR) was 
62, 7 points. Both moderate–severe liver disease and CCI were statistically higher in patients who 
died in the hospital. A total of 24.7% of all patients were reported as cachectic upon physical 
examination, with median albumin 2.6 (2.1, 3.3) g/dL and a statistically high proportion of 
cachectic patients and lower albumin figures among those who did not survive. 
 
The most common cause for admission was severe sepsis/septic shock (SS/SS) (49.5%), followed 
by admissions with a cardiologic origin (19.4%) (Appendix A. Supplementary data, Table e2). 
61.3% of patients who died had been admitted due to SS/SS. 
 
APACHE II scores upon admission and SOFA scores during the first 24 h were 18.05 ± 9.05 and 
6,3, 9 respectively. A total of 60.8% of patients required respiratory support with 
invasive mechanical ventilation (MV) (length of MV: 7 days [2, 13.75]); 40.3% 
received vasoactive drugs (VADs) (length of VADs: 2 [1, 4] days), and 11% required RTTs (5 [2, 
11] days). Patients who died in the hospital presented significantly higher severity scores at 
admission and required more frequent respiratory, haemodynamic and renal support. 
 
Comparison between the three periods is shown in Table 2. During the study period, the figures for 
hospital mortality did not vary significantly, being 30.3% among patients admitted in 2000–2004, 
31.8% in 2005–2009 and 36.4% in 2010–2014 (annual percentage of change = 1.6; 95% CI −2.3 to 
5.8, p = 0.39). 
  
Table 2. Comparison based on year of admission. 
 
2000–2004 
(n = 66) 
2005–2009 
(n = 129) 
2010–2014 
(n = 88) 
p value 
     
Age 40.41 ± 10.40 42.27 ± 8.66 47.22 ± 9.18 <0.01 
HIV infection 
New diagnosis 7 (10.6) 10 (7.8) 16 (18.2) 0.06 
Years of infection 6 (1, 11) 10 (5, 16) 12 (1.25, 19) <0.01 
AIDS 45 (68.2) 102 (79.1) 48 (54.5) <0.01 
CD4 count (cell/mL) 178.5 (54, 382.5) 153.5 (63.5, 400) 179.0 (45, 465) 0.91 
Viral load 4.4 (2.60, 5.37) 3.3 (0, 5.3) 1.61 (0, 4.97) <0.01 
Viral load suppressed 5 (10.4) 27 (26.0) 32 (42.1) <0.01 
HAART 26 (39.4) 72 (55.8) 57 (64.8) <0.01 
HAART in ICU 15 (22.7) 46 (35.7) 50 (56.8) <0.01 
Comorbidities 
M–S liver disease 3 (4.5) 20 (15.5) 14 (15.9) 0.06 
Charlson Comorbidity Index 6.50 (2, 7) 7 (6, 8) 6 (1.25, 7.75) <0.01 
Diagnosis at admission 
SS/SS 27 (40.9) 70 (54.3) 43 (48.9) 0.21 
PCP 10 (15.2) 7 (5.4) 8 (9.1) 0.07 
Cardiac 19 (28.8) 19 (14.7) 17 (19.3) 0.06 
Trauma 6 (9.1) 6 (4.7) 7 (8.0) 0.43 
Neurological 2 (3.0) 3 (2.3) 6 (6.9) 0.22 
Organ support 
Mechanical ventilation 37 (56.1) 75 (58.1) 60 (68.2) 0.22 
Vasoactive drugs 19 (28.8) 57 (44.2) 38 (43.2) 0.09 
Renal replacement therapy 4 (6.1) 13 (10.1) 14 (15.9) 0.14 
Severity scores 
APACHE II 14 (9, 20.50) 18 (12, 26) 20 (13, 26) <0.01 
SOFA score 4 (1.25, 7) 7 (3, 11) 7 (3, 9) <0.01 
SOFA score 72 h 3 (1, 6) 4 (2, 7.75) 6 (2, 10) <0.01 
SOFA 0–72 h 0 (−1, 0) 0 (−1, 0) 0 (−1, 0) <0.01 
Length of stay 
ICU 4 (1.75, 15) 5 (2, 13) 5.5 (2, 11) 0.73 
Hospital 17 (8, 31) 20 (9, 38) 16 (8, 42.25) 0.78 
Mortality 
ICU mortality 17 (25.8) 30 (23.3) 24 (27.3) 0.79 
Hospital mortality 20 (30.3) 41 (31.8%) 32 (36.4) 0.69 
     
 
Numbers reported as n (%) and mean ± standard deviation or median (interquartile range). 
HAART: high-activity antiretroviral therapy; M–S liver disease: moderate–severe liver disease, PCP: Pneumocystis 
jiroveci pneumonia. 
In Table 3 we present differences between patients who were receiving HAART at the moment 
they were admitted to ICU with whose were not and, on the other hand, between those patients 
who received HAART during their ICU stay and those who not. 
Table 3. Comparison between patients who receive HAART and those who not (pre-ICU admission and during ICU stay). 








(n = 172) 
Yes 
(n = 111) 
p 
        
Age 41.2 ± 8.8 45.2 ± 9.9 <0.01  42.1 ± 8.6 45.4 ± 10.7 <0.01 
Male sex 92 (71.9) 114 (73.5) 0.75  130 (75.6) 76 (68.5) 0.19 
Admission from ED 73 (57.0) 87 (56.1) 0.88  96 (55.8) 64 (57.7) 0.76 
HIV infection 
HAART pre-ICU admission     70 (45.2) 85 (54.8) <0.01 
HAART in the ICU 26 (20.3) 85 (54.8) <0.01     
AIDS 100 (78.1) 95 (61.3) <0.01  124 (72.1) 71 (64.0) 0.15 
Years of infection 6 (0, 12) 12.5 (6.25, 18) <0.01  9 (2, 16) 10 (3.75, 17) 0.34 
CD4 count (cell/mL) 72 (30, 182) 293 (130.25, 518.25) <0.01  160 (53, 317) 185 (54.75, 518,25) 0.12 
Viral load (log) 5.3 (4.35, 5.7) 1.6 (0, 2.78) <0.01  4.3 (2, 5.3) 1.8 (0, 4.9) <0.01 
Viral load suppressed 4 (4.3) 60 (44.4) <0.01  28 (22.0) 36 (35.6) 0.02 
Days until start of HAART 6 (4, 14) 0 (0, 1) <0.01   1 (0, 5)  
Comorbidities and nutritional status (see Appendix A. Supplementary data) 
M-S liver disease 12 (9.4) 25 (16.1) 0.09  27 (15.7) 10 (9.0) 0.10 
Hepatitis C Virus (HCV) 79 (61.7) 91 (58.7) 0.61  118 (68.6) 52 (46.8) <0.01 
Charlson Comorbidity Index 7 (6, 7) 6.5 (2, 8) 0.48  7 (3.25, 8) 6 (2, 7) 0.08 
Cachexia 39 (30.5) 31 (20.0) 0.04  40 (23.3) 30 (27.0) 0.47 
Albumin (g/dL) 2.4 (2, 2.9) 2.85 (2.2, 3.6) <0.01  2.5 (2.03, 3.10) 2.8 (2.2, 3, 41) <0.01 
Diagnosis at admission (see Appendix A. Supplementary data) 
Severe sepsis/septic shock 81 (63.3) 59 (38.1) <0.01  87 (50.6) 53 (47.7) 0.64 
PCP 22 (17.2) 3 (1.9) <0.01  14 (8.1) 11 (9.9) 0.61 
Cardiac 10 (7.8) 45 (29) <0.01  24 (14.0) 31 (27.9) <0.01 
Organ support during admission 
Mechanical ventilation 88 (68.8) 84 (54.2) 0.01  109 (63.4) 63 (56.8) 0.27 
Vasoactive drugs 56 (43.8) 58 (37.4) 0.28  75 (43.6) 39 (35.1) 0.16 
Renal replacement therapy 15 (11.7) 16 (10.3) 0.71  18 (10.5) 13 (11.7) 0.74 
Complications (see Appendix A. Supplementary data) 
Superinfection 22 (17.2) 19 (12.3) 0.24  20 (11.6) 21 (18.9) 0.09 
HAART-related* 7 (26.9) 3 (3.5) <0.01   10 (9.0)  
Severity scores 
APACHE II 20 (13, 26) 15 (10, 23) <0.01  19 (13, 26) 15 (9, 23) <0.01 
SOFA score 6 (4, 10) 5 (2, 9) 0.02  7 (3.25, 10) 4 (2, 8) <0.01 
SOFA score 72 h 5 (2, 8.25) 4 (2, 8) 0.16  5 (2, 9) 4 (1, 7.5) 0.21 
Outcomes 
ICU mortality 35 (27.3) 36 (23.2) 0.42  53 (30.8) 18 (16.2) <0.01 
Hospital mortality 50 (39.1) 43 (27.7) 0.04  69 (40.1) 24 (21.6) <0.01 
ICU LOS 6 (2, 15) 4 (2, 10) 0.04  4 (1, 9) 8 (3, 17) <0.01 
Hospital LOS 23.5 (12.25, 40.75) 14 (7, 31) <0.01  16.5 (8, 33,25) 23 (9, 43) 0.02 
        
We found HAART-related complications in less than 10% of patients who receive treatment 
during ICU stay (Appendix A. Supplementary data, Table e3), more frequently in patients without 
previous ART (26.9 vs 3.5%, p < 0.01). 
 
Factors significantly associated with hospital mortality on univariate analysis were included in the 
final regression model, and we found that only admission from a site other than the ED ((OR 3.64, 
95% CI 1.30–10.20, p = 0.01), the existence of moderate–severe liver disease (OR 5.65, 95% CI 
1.11–28.87, p = 0.04), APACHE II (OR 1.14, 95% CI 1.04–1.26, p < 0.01) and SOFA at 72 h (OR 
1.19, 95% CI 1.02–1.40, p = 0.03) maintained a statistically significant relationship with hospital 
mortality (Table 4). 
Table 4. Variables related to hospital mortality. Univariate and multivariate logistic regression analysis. 
 
Univariate logistic regression 
analysis 
 
Multivariate logistic regression 
analysis 
Variable OR 95%CI P value  OR 95%CI P value 
        
Male sex 1.71 0.95–3.09 0.08     
Age 1.01 0.98–1.03 0.73     
Admission not from ED 3.94 2.33–6.65 <0.01  3.64 1.30–10.20 0.01 
Comorbidities and nutritional status 
M-S liver disease 2.45 1.22–4.94 0.01  5.65 1.11–28.87 0.04 
Charlson Comorbidity Index 1.11 1.02–1.22 0.02  0.99 0.71–1.38 0.94 
Cachexia on physical 
examination 
2.67 1.53–4.67 <0.01  1.17 0.35–3.97 0.80 
Albumin (per g/dL) 0.48 0.32–0.71 <0.01  0.87 0.33–2.32 0.79 
HIV infection 
Years of infection 0.98 0.94–1.01 0.16     
Diagnosis during actual 
admission 
2.43 1.17–5.07 0.02  1.55 0.32–7.56 0.59 
Not receiving HAART 1.67 1.01–2.75 0.04  1.49 0.44–5.11 0.52 
HAART during ICU stay 0.41 0.24–0.71 <0.01  0.37 0.12–1.17 0.09 
AIDS 1.72 0.98–3.02 0.06     
CD4 count 0.99 0.99–0.99 <0.01  0.99 0.99–1.00 0.09 
Viral load 1.16 1.02–1.31 0.02  1.11 0.83–1.49 0.48 
Viral load suppressed 0.76 0.40–1.44 0.40     
Diagnosis at admission 
Severe sepsis/septic shock 2.04 1.23–3.39 <0.01  0.65 0.18–2.37 0.52 
Cardiological 0.28 0.12–0.65 <0.01  0.66 0.05–8.67 0.76 
Neurological 3.79 1.08–13.27 0.04  3.40 0.23–49.93 0.37 
Trauma 0.52 0.17–1.63 0.26     
Organ support during admission 
Mechanical ventilation 7.34 3.76–14.35 <0.01  2.90 0.53–15.97 0.22 
Vasoactive drugs 4.26 2.52–7.21 <0.01  0.75 0.22–2.57 0.64 
Renal replacement therapy 6.23 2.74–14.18 <0.01  2.22 0.57–8.63 0.25 
Complications 
Superinfection 2.79 1.42–5.47 <0.01  2.94 0.91–9.43 0.07 
Severity scores        
APACHE II 1.16 1.11–1.20 <0.01  1.14 1.04–1.26 <0.01 
SOFA score 1.24 1.16–1.33 <0.01  0.80 0.64–1.00 0.06 
SOFA score 72 h 1.22 1.13–1.32 <0.01  1.19 1.02–1.40 0.03 
        
 
ED: Emergency department; HAART: high-activity antiretroviral therapy; OR: odds ratio; CI: confidence interval. 
  
Discussion 
Our study describes the HIV-infected patient population that required ICU admission over a 
relatively long period (15 years), and during the current period of ART. Consistent with most 
publications to date, we found that critical patients infected with HIV are young and 
predominantly male. In our study, we could not prove a relation between immunovirological or 
nutritional status, reason for admission or need for organ support and hospital mortality. Variables 
related with higher hospital mortality in our patients were severity scores (APACHE II at 
admission and SOFA at 72 h), moderate–severe liver disease and admission form hospital ward. 
Our data provide important insight regarding the complex management of hospitalised HIV-
infected patients. Sepsis remains the leading cause of ICU admission in the current HAART era. 
Mortality, although higher, increasingly approximates that of non-HIV patients. 
 
Our population has a long-standing history of clinical course of infection (median nine years from 
diagnosis, increasing up to 12 in last five years of our study) and very few patients were diagnosed 
during their current admission (less than 12%). These data are similar to those recently published 
describing industrialized countries.22, 28, 33 However, in the studies by Chiang et al. and Xiao et al., 
the clinical course of the disease was much shorter (less than a year), with a high percentage of 
diagnoses during admission (approximately 50%).26, 29 
 
At present, it is widely currently recommended that HAART be administered to all HIV-infected 
patients, regardless of immunovirological profile or symptoms. However, despite that proportion 
of patients receiving HAART is increasing, only 54.8% of our patients were under HAART at 
admission. These data are comparable to those reported by other countries from our 
region,18, 28, 33 and the level in Spain is higher than in the studies published from countries such as 
Australia, Brazil, Taiwan and China (in which less than 40% of patients received 
ART),22, 26, 27, 29 but far from the 71% reported in the USA by Akgün et al.20 This variability in the 
percentage of patients who receive ART is reflected in their CD4 T-lymphocyte counts at 
admission. Among our patients, the median was 167 cells/mm3 (53.5, 414.0); in studies with a 
lower percentage of patients receiving ART, the CD4 count is lower, even falling below 
50 cells/mm3.26, 29 
 
As in other recent studies, despite our patients’ relatively good immunovirological conditions, 
almost half were admitted to the ICU because of infection.22, 23 
 
Consistent with previous reports,22, 31 13.1% of our patients presented with chronic liver 
disease with cirrhosis or PHT. HCV co-infection is very common in HIV patients and varies 
between 15% and 60%19, 31; in our sample, 60.1% of patients presented with HCV co-infection. 
 
ICU and hospital mortality (25.1% and 32.9%, respectively) observed in our study was 
comparable to the figures reported for other industrialized 
countries6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and lower than those reported for developing 
countries (higher than 40%)24, 25, 26, 27, 28, 29, 30 and in other Spanish studies.31, 32 These observed 
mortality differences are probably of multifactorial origin and impact both factors such as extra-
hospital treatment for these patients (follow-up in consultations, HAART, management of 
comorbidities, etc.) and the care received during hospital admission (ICU admission criteria, organ 
support provided, etc.). 
 
We did not find a significant relationship between immunovirological condition, receiving ART, 
or years of evolution of infection and hospital mortality. These data coincide with those reported in 
most,8, 10, 15, 16, 18, 19, 22, 26, 27, 29, 33, 36, 37 although not all,11, 13, 17, 22, 24, 26, 28, 38 studies published to date. 
Probably the difficulty in detecting an independent relationship between mortality and 
inmunovorological status lies in the fact that patients who receive HAART have not only a higher 
CD4 count and a lower VL but also a better nutritional status and a different reason for ICU 
admission. Nevertheless, a larger sample size could, perhaps, give us a statistically significant 
relation of CD count with mortality. 
 
Furthermore, some studies have related the use of HAART during the ICU stay to lower intra-ICU 
mortality without impacting long-term survival.19, 25, 27, 33 A meta-analysis including 12 
retrospectives studies, published in 2017, showed a significant benefit on short-term mortality 
when HAART is received during ICU stay, but long-term benefit remains unclear.39 Herein, 
despite we found a lower hospital mortality in patients having HAART both previously and during 
ICU stay, we could not prove a significant relationship between receiving HAART and hospital 
mortality. Although is possible that inclusion of a higher number of patients would change this, 
there were important differences between these groups. On the one hand, patients under HAART 
at admission had a better immunovirological and nutritional status, less ICU admissions caused by 
sepsis and lower severity scores at admission. On the other hand, severity scores were higher in 
patients who did not receive HAART during ICU stay and patients who receive HAART on ICU 
were more frequently under treatment at admission (with a consequent better immunovirological 
status). It's remarkable that only 54% patients with chronic HAART treatment receive it during 
ICU stay. HAART administration in ICU is complicated due to limited availability of parenteral 
ART and unknown pharmacokinetics of enteral administration through nasogastric tubes in 
patients receiving mechanical ventilation or in shock, risk of potential drugs interactions and risk 
of provoking immune reconstitution inflammatory syndrome. The delay in the start of HAART in 
ICU was 1 (0, 5) day, but was higher in patients with invasive mechanical ventilation [4.5 (1, 7) 
compared with 0 (0, 1) days in no-ventilated patients, p < 0.01] or in shock [5 (1, 8.5) vs 1 (0, 3) 
days]. 
 
Just as in other studies,21, 27, 28, 29, 30 delayed ICU admission from patient hospital arrival (here 
defined as admission not from E.D.) significantly increased the risk of death during the hospital 
stay. Factors such as initially inadequate treatment, poor response to that treatment, or onset of 
complications during the hospital stay may justify the relationship between delayed admission and 
higher mortality. 
 
In the current era, in which HIV infection is controllable with ART, comorbidities play an 
increasingly important role in patient prognosis. Patients with a history of moderate–severe liver 
disease have a higher risk of hospital death in our study and those by Barbier et al., Turvey et al. 
and Medrano et al.21, 22, 31 We did not find relation between other comorbidities and mortality. 
 
It has been proposed that, nowadays, the mortality among ICU-admitted HIV patients is related to 
the severity of their acute event. Higher severity scores among critical patients at admission, such 
as APACHE II or SAPS II, have been related to higher mortality.19, 21, 22, 25, 27, 28, 33 This was 
observed in our study, in which risk of death increases close to 20% for each point on SOFA score 
evaluated at 72 h and more than 10% for each point on the APACHE II score. However, we did 
not find a significant relationship between the SOFA at ICU admission and mortality, which 
probably reflects that in order to establish the prognosis it is more important to assess the response 
to treatment than the initial organ dysfunction. Regarding the need for organ support, evidence is 
contradictory, with discrepancies as to the relationship between hospital mortality and the need 
for respiratory support with invasive MV,19, 21, 22, 25, 27, 29 for VADs19, 21, 22 and for RRTs.21, 22, 29 In 
our study, the need for support did not predict hospital mortality once we adjusted for severity, 
reason for admission and comorbidities. 
 
While some studies have reported poorer prognosis in patients admitted to the ICU because of 
infection,25, 30 we did not detect any relationship between the reason for ICU admission and 
prognosis. These differences may be based on patients’ immunovirological profiles at admission, 
because more immunosuppression increases their risk of admission due to OIs, which then lead to 
a worse prognosis. 
  
Finally, we found important differences between the three periods (2000–2004, 2005–2009 and 
2010–2014). First, patients were older and with more years living with HIV in most recent periods. 
Second: proportion of patients receiving HAART also increases significantly, with a consequent 
decrease in HIV viral load. Third, severity scores were higher in most recent periods. We did not 
find changes in mortality over time (Table 2). 
 
Our study is not without limitations. First, it was observational and retrospective. Second, although 
two sites took part, both are in the same geographic setting, limiting the extent to which we can 
generalize the results. Third, data on ART administration were obtained from clinical records; no 
drug level tests were performed either at admission or during the ICU stay. Thus, it is possible that 
patients noncompliant with treatment were not detected. Fourth, only physical examination 
and albumin levels at admission were used to evaluate nutritional status; we do not have other 
useful data such as body mass index. Fifth, a recruitment bias cannot be ruled out, because neither 
of the two units taking part have defined ICU admission criteria for HIV patients; we identified 
patients retrospectively using the hospital records system. Finally, our study includes patients over 
15 years, which may reduce its external validity. 
Conclusions 
Delayed ICU admission, comorbidities and severity of critical illness, determine the prognosis of 
HIV-infected patients admitted to the ICU. We did not detect any impact of immunovirological or 
nutritional condition, reason for admission, or need for organ support during admission. Based on 
these data, HIV patients should receive the same level of care as non-HIV-infected patients, 
regardless of their immunological or nutritional condition. We can not prove a relationship 
between receiving HAART and prognosis, but we have shown significant differences between 
patients who receive and do not receive treatment before ICU admission (better nutritional and 
inmunovirologic status, and less severity, sepsis-related admissions and need for mechanical 
ventilation in HAART patients) and during their ICU stay (better immunological status, less HCV-
infected patients and less severity and more cardiac-related diagnosis in patients who received 
HAART). 
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